Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015914 | 0.97 | SLC6A4 (0.74) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL5016014 | 0.89 | SLC6A4 (0.59) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4265133 | 0.88 | SLC6A4 (0.81) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL14296822 | 0.86 | SLC6A4 (0.83) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4264531 | 0.86 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4272477 | 0.86 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4265303 | 0.86 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4267845 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4257127 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL4264505 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008002818-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | HNMT, HRH3, HRH4 | SLC6A4 6/4885HRH3 2/4885SLC6A2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.